Basics Vericel Corporation Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases. IPO Date: November 25, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.83B Activated in VL: True Average Daily Range Avg Daily Range: $0.57 | 2.54% Avg Daily Range (30 D): $0.92 | 2.39% Avg Daily Range (90 D): $0.87 | 2.44% Institutional Daily Volume Avg Daily Volume: .45M Avg Daily Volume (30 D): .49M Avg Daily Volume (90 D): .57M Trade Size Avg Trade Size (Sh.): 96 Avg Trade Size (Sh.) (30 D): 48 Avg Trade Size (Sh.) (90 D): 52 Institutional Trades Total Inst.Trades: 2,958 Avg Inst. Trade: $2.5M Avg Inst. Trade (30 D): $2.31M Avg Inst. Trade (90 D): $2.37M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.96M Avg Closing Trade (30 D): $3.74M Avg Closing Trade (90 D): $3.24M Avg Closing Volume: 89.72K     News Nov 6, 2025 @ 5:02 PM Brown Capital Discloses $31 Million Sale of Verice... Source: Jonathan Ponciano Aug 14, 2025 @ 6:22 PM MediWound Revenue Jumps 43% in Q2 Source: Na Aug 5, 2025 @ 7:14 PM Vericel Q2 Revenue Jumps 20% Source: Jesterai Aug 1, 2024 @ 11:55 AM Vericel Reports Second Quarter 2024 Financial Resu... Source: Vericel Corporation Jul 30, 2024 @ 6:00 AM Global Regenerative Medicine Market Size To Worth ... Source: Spherical Insights & Consulting Financials   TTM Q3 2025 Q2 2025 Basic EPS $.26 $.1 $-.01 Diluted EPS $.25 $.1 $-.01 Revenue $ 258.72M $ 67.5M $ 63.24M Gross Profit $ 190.97M $ 49.59M $ 46.61M Net Income / Loss $ 13.08M $ 5.07M $ -.55M Operating Income / Loss $ 7.11M $ 3.45M $ -2.03M Cost of Revenue $ 67.75M $ 17.92M $ 16.63M Net Cash Flow $ 30.05M $ 19.87M $ .83M PE Ratio 144.92     Splits Oct 16, 2013:   1:20 Feb 18, 2010:   1:8